Breadcrumb Home Studies Studies Search Filter Research Area All Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentOpen to AccrualParticipants Off Study and Primary Analysis CompletedPendingWithdrawn Sort Study Number AscStudy Number Desc Submit Search Showing 15 studies. IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum. DAIDS Number 38609 Research Area Therapeutics Study Status Closed to Follow Up IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Closed to Follow Up IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Closed to Follow Up P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) Given in Combination with an Individualized Rifampin-Resistant Tuberculosis (RR-TB) Therapy in Infants, Children and Adolescents with RR-TB Disease, Living with or without HIV. DAIDS Number 11884 Research Area Tuberculosis P1084s: Maternal Infant TDF Toxicity Safety DAIDS Number 10790 Research Area Therapeutics Study Status Closed to Follow Up P1081: 3 Regimens for HIV Infected Women initiating ARV regimens for PMTCT DAIDS Number 10770 Research Area Mother to child transmission Study Status Concluded 1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival) DAIDS Number 10779 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed 1077FF: PROMISE 1077FF DAIDS Number 10778 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed 1077BF: PROMISE 1077BF DAIDS Number 10777 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed Pagination Current page 1 Page 2 Next page Next
IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum. DAIDS Number 38609 Research Area Therapeutics Study Status Closed to Follow Up
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Closed to Follow Up
IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Closed to Follow Up
P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) Given in Combination with an Individualized Rifampin-Resistant Tuberculosis (RR-TB) Therapy in Infants, Children and Adolescents with RR-TB Disease, Living with or without HIV. DAIDS Number 11884 Research Area Tuberculosis
P1084s: Maternal Infant TDF Toxicity Safety DAIDS Number 10790 Research Area Therapeutics Study Status Closed to Follow Up
P1081: 3 Regimens for HIV Infected Women initiating ARV regimens for PMTCT DAIDS Number 10770 Research Area Mother to child transmission Study Status Concluded
1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival) DAIDS Number 10779 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
1077FF: PROMISE 1077FF DAIDS Number 10778 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
1077BF: PROMISE 1077BF DAIDS Number 10777 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed
